KRT16 and melanoma: Thus far, 8 out of 21 GLI targets we chose to validate—KRT16, S100A9, SOX9, BIRC7, EBI3, FLG, SAMMSON and SPRY2—were already implicated in melanoma pathogenesis [34,46,47,51,52,64,79,81,82,87,101,120].